Thursday , October 28 2021

Cadila Healthcare’s arm receives approval for Haloperidol Decanoate Injection

Cadila Healthcare’s wholly-owned subsidiary company — Liva Pharmaceuticals has received the approval from the United States Food and Drug Administration (USFDA) for Haloperidol Decanoate Injection, 50 mg (base)/mL and 100 mg (base)/mL, single-dose vials, 250 mg (base)/5 mL (50 mg (base)/mL) and 500 mg (base)/5 mL (100 mg (base)/mL), multiple-dose vials (US RLD – Haldol Decanoate Injection, 50 mg (base)/mL and 100 mg (base)/mL).

It will be manufactured at Liva Pharma’s manufacturing facility at Vadodara. Haloperidol is used in the treatment of schizophrenia and for the control of tics and vocal utterances of Tourette syndrome.

Cadila Healthcare is an India-based pharmaceutical company. The company’s subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.

Please share this news
<div id="taboola-below-article-thumbnails"></div>
<script type="text/javascript">
  window._taboola = window._taboola || [];
    mode: 'thumbnails-a',
    container: 'taboola-below-article-thumbnails',
    placement: 'Below Article Thumbnails',
    target_type: 'mix'